Natalizumab

Details

Files

Generic Name:

Natalizumab

Project Status:

Complete

Therapeutic Area:

Multiple Sclerosis, relapsing-remitting

Manufacturer:

Biogen Idec Canada Inc.

Brand Name:

Tysabri

Project Line:

Reimbursement Review

Project Number:

SR0133-000

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Resubmission

Indications:

Multiple Sclerosis, relapsing-remitting

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

February 25, 2009

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : May 6, 2008